A Bioavailability Study of MIV-711 Oral Formulations in Healthy Volunteers

计划入组 18 人 · 首次发布于 2018 年 2 月 23 日

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

计划入组 30 人 · 首次发布于 2014 年 8 月 1 日

A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients

计划入组 244 人 · 首次发布于 2016 年 3 月 10 日

MIV-828

MIV-247

MIV 160

CEL-SCI

United States

Adaptimmune Therapeutics

United Kingdom

Mines D`or Orbec Inc

United States

Kyverna's CAR-T Therapy for Stiff Person Syndrome Advances to BLA Filing Based on Natural History Study

Neurologists See CAR T Potential in Neuro-Immune Diseases, but Safety and Logistics Will Shape Adoption

Kyverna Therapeutics Initiates First-Ever Rolling BLA for CAR T Therapy in Stiff Person Syndrome, Paving Way for Autoimmune Neurology Revolution